A phase 1, randomized, double-blind, single-center, placebo-controlled first-in-human trial to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of RBD7007 in healthy participants
RC01T001
Phase 1 other active
Quick answer
A phase 1, randomized, double-blind, single-center, placebo-controlled first-in-human trial to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of RBD7007 in healthy participants for Complement-mediated diseases is a Phase 1 program (other) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Lacuna Pharma Pty Ltd
- Indication
- Complement-mediated diseases
- Phase
- Phase 1
- Modality
- other
- Status
- active